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Monoclonal antibodies directed against surface antigens expressed on subpopula- 
tions of lymphoid cells might be used for selective interference with function mediated 
by  these  structures.  Several  anti-human  T  cell  monoclonals have  been  shown  to 
interfere  with  immune  responses  when  present  in  an  assay.  A  class  of 33,000  Mr 
antigens expressed on cytotoxic/suppressive cells are detected by OKT5, OKT8, and 
OKT8a antibodies.  Addition of these antibodies to a  lytic assay reduces lysis  (1,  2). 
Anti-Leu-2a, binding to the same population of cells, precipitates molecules of 32,000 
and  43,000  Mr  (3). In the  presence of this  antibody, the  mixed leukocyte reaction 
(MLR) is diminished, and eytotoxic T  lymphocyte (CTL) activity is prevented (4, 5). 
Another cell surface antigen detected by OKT3 antibodies is present on all peripheral 
T  cells  and has an Mr of 19,000  (2). Interference with this antigen by the antibody 
gives rise to a mitogenic response, but in higher concentrations the induction ofT cell 
responses  as well  as  the  execution  of T  killing  is blocked  (6,  7).  In  this  study, we 
approached the question of what mechanisms are interfered with by the presence of 
such antibodies in a  lytic assay. Out of a  panel of seven anti-human lymphoid cell 
monoclonals,  three  were  shown  to  diminish  CTL  activity,  whereas  none  affected 
natural  killer  cell  (NK)  activity.  OKT3  and  Leu-2a  antibodies  were  investigated 
further.  In both cases, the inhibition  resulted  from an interaction with  the effector 
cells.  The inhibition  induced  by Leu-2a antibodies was rapidly reversible,  whereas 
anti-OKT3 had  a  more long-lasting influence.  With  the  aid  of a  single cell  assay, 
anti-Leu-2a was shown to block a  target-binding step,  whereas anti-OKT3 allowed 
such binding but inhibited the subsequent lytic step. 
Materials and Methods 
Cell Culture.  Peripheral  blood mononuclear cells were prepared  from the blood of healthy 
volunteers by Fieoll-Hypaque  tloatation.  MLR were established  at  1 X 106 responders and  1 
×  106 2,500 rad irradiated  stimulators  per ml. Goneanavalin  A (Con A) stimulation  of the cells 
to be used as targets was performed at 5 X l0  s cells/ml using 2.5/xg/ml of Con A. Staphylococcus 
aureus stimulation  was effected at  1 ×  106 cells/ml  with 0.1% (vol/vol) formalin-fixed bacteria 
(8). The stimulated  leukoeytes were depleted  of sheep  erythrocyte-rosetting  cells (9)  before 
being used as B cell targets.  As an NK-sensitive target,  MOLT-4 was used  (10). Cells were 
grown in RPMI 1640, supplemented  with 2 mM gtutamine,  50 ~M 2-mercaptoethanol,  and 50 
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IU penicillin and 60 gg streptomycin per ml. The medium contained 5%  responder plasma 
with  10 IU heparin per ml in the lymphocyte stimulations, and 5% heat-inactivated fetal calf 
serum in the tumor cultures and lytic and binding assays. 
Monoclonal Antibodies.  Anti-Leu-1, anti-OKT3, and anti-OKT-11 detect all human T  cells 
(11, 6,  12); anti-Leu-2a and anti-OKT8 bind to the cytotoxic/suppressive T  subset (3, 1); anti- 
Leu-3a bind to helper T  cells (3);  and anti-OKM  1 has affinity for monocytes (13).  The OK 
series of antibodies were donated by Ortho Pharmaceutical, Raritan, NJ. The Leu antibodies 
were provided by Becton, Dickinson & Co., Sunnyvale, CA. Effector cells were preincubated 
with the antibodies for 30 min at 37°C before being mixed with target cells. 
Chromium Release Assay.  Target ceils were labeled with 5:chromium and added to dilutions 
of effector cells made in duplicate or triplicate in V-bottomed microtiter plates. After a  4-h 
incubation  at  37°C,  the  plates were  spun,  and  aliquots of supernatant  were  collected for 
determination  of radioactivity. Specific release was  calculated as  ([experimental release  - 
spontaneous release]/[maximum release -  spontaneous release]) X  100%. 
Single  Cell Binding  and  Cytotoxicity Assay.  Binding  of  target  cells  to  effectors  and  their 
subsequent  lysis was  investigated according to  Grimm et  al.  (14),  modified as pointed out 
below. In brief, effector cells were preincubated in I0 gg/ml anti-OKT3, 5 #g/ml anti-Leu-2a, 
or medium. They were not washed before the assay. Target cells were labeled with carboxy 
fluorescein diacetate (15) to allow their distinction from effectors under a fluorescence micro- 
scope. Equal volumes of effector and target cells were mixed at a one to one ratio and spun 
together at 500 g. After 10 rain incubation at 37°C, the pellet was resuspended and the cells 
mixed with the agarose solution and then dripped onto petri dishes. Parallel dishes were either 
scored for binding immediately or incubated with medium for 3 h and then stained with trypan 
blue and  fixed. The percentage target binding cells (TBC)  was calculated after scoring 400 
effector cells. The  fraction of conjugates containing dead cells after the 3-h incubation was 
expressed as the percentage cytotoxic target binding cells (CTBC), estimated by counting 100 
conjugates. 
Results 
Three Monoctonal  Antibodies Inhibit T  Cell Killing without Affecting NK Activity. A  panel 
of monoclonal antibodies was added at 2 gg/ml for a  30-min preincubation of MLR 
cells. These were then assayed for lytic activity against Con A  blasts established from 
the stimulator and against an NK-sensitive tumor cell line, MOLT-4. The antibody 
concentration at the highest effector to target ratio investigated was  1 gg/ml.  Fig.  1 
gives the mean reduction in lytic activity by the effectors. Reduced CTL activity was 
seen  after  treatment  with  OKT3,  OKT8,  and  Leu-2a  antibodies  (P <  0.001).  No 
monoclonals  affected  NK  activity.  Control  experiments  using  S.  aureus-stimulated 
leukocytes depleted of T  cells clarified that the inhibition resulted from an interaction 
with  the effector cells for anti-OKT3  and  Leu-2a,  the two  antibodies chosen  for a 
more detailed study (data not shown). This was previously shown for anti-OKT3 by 
Platsoucas and Good (2). 
Inhibition by Leu-2a Antibodies Is Rapidly Reversible.  The anti-OKT3-induced inhibi- 
tion of lysis was shown to be proportionally increased by applying the same amount 
of antibody in a  smaller volume during preincubation. For anti-Leu-2a, the extent of 
the  inhibition  was  set  by  the  concentration  of antibody  in  the  test  (Fig.  2).  This 
indication of differential reversibility of the inhibition exerted by OKT3  and Leu-2a 
antibodies was confirmed by washing the effectors after the antibody treatment. With 
this protocol, anti-Leu-2a failed to affect lysis, whereas for anti-OKT3, inhibition was 
not affected. After resting the OKT3-treated and subsequently washed cells for 3 h  at 
37°C, inhibition was reduced by 50%, and control levels of lysis were usually obtained 
by 6  h.  The faster reversibility for the anti-Leu-2a inhibition of CTL  activity might LANDEGREN ET  AL.  BRIEF  DEFINITIVE REPORT  1581 
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Fxc.  2.  MLR  cells  were  treated  in  graded  amounts  of  OKT3 
(C),O) or Leu-2a (D,B) antibodies.  Cell concentration during anti- 
body treatment was two times (O,1-1) or 20 times (Q,1) that in the 
assay. The antibody concentrations, after diluting the preincubated 
effectors and mixing with target cells, are indicated on the abscissa. 
The ratio of targets to effectors was 50:1. Percent lysis in the absence 
of antibody was 52.9%. 
reflect a  faster turnover rate for the corresponding  surface antigen or a  lower avidity 
of the antibody. 
OKT3 and Leu-2a Antibodies Prevent Target Lysis by Different Mechanisms.  To analyze 
at what  step the lytic process is inhibited by these antibodies,  we applied a  single cell 
assay in agarose. In Table I, results are presented from experiments where anti-OKT3 
was added  to effectors before introducing them to their target cells.  Decreased  target 
lysis  was  evident  from  chromium  release  data.  The  number  of effector  cells  that 
bound  targets  was  not  detectably  influenced.  Bound  targets,  however,  survived  the 
interaction more often when the effectors had been treated with anti-OKT3.  The case 
for  anti-Leu-2a  was  investigated  in  another  set  of MLR  (Table  II).  With  a  similar 
overall  effect  upon  lysis,  these  antibodies  could  be  shown  to  substantially  reduce 
target  binding.  The  cytotoxicity  was  determined  in  a  standard  chromium  release 
assay at an effector to target ratio of 20:1.  In the binding test a  ratio of 1:1 was used. 
This  difference,  together  with  the  prevented  recycling of CTL  in  the  agarose  test, 
contributes  to the lack of direct correspondence between the percent cytotoxicity and 
numbers  obtained  in the agarose test. 1582  LANDEGREN ET AL.  BRIEF  DEFINITIVE REPORT 
TABLE I 
OKT3 Monoclonal Antibodies Prevent Cytotoxicity by Reducing Lytic Activity 
without Affecting the Target-Binding Ability 
MLR  Antibody  Target  Cytotoxicity  TBC  CTBC 
%  %  % 
A  anti-B  0  B  35.4  8.5  60 
A  anti-B  OKT3  B  8, I  8.0  27 
A  anti-B  0  A  ND*  1.5  0 
A  anti-C  0  C  37.4  6.8  71 
A anti-C  OKT3  C  9.9  5.8  24 
A anti-C  0  A  ND  1.4  0 
D  anti-E  0  E  44.1  10.0  36 
D  anti-E  OKT3  E  7,5  9.6  14 
D  anti-E  0  D  -7.8  ND  ND 
Three  MLR  were  investigated  for lytic activity in  the  presence  or absence  of OKT3 
antibodies.  Cytotoxicity  was  measured  in  a  chromium  release  assay.  The  percentage 
TBC  was determined  using a  single cell  assay.  The  fraction  of conjugates containing 
killed cells after a  3 h  incubation  is represented  as C-'TBC. 
* Not done, 
TABLE  II 
Leu-2a Monoclonal Antibodies Prevent Cytotoxicity by Inhibiting Target 
MLR  Antibody  Target  Cytotoxicity  TBC  CTBC 
%  %  % 
F anti-G  0  G  33.7  9.9  40 
F anti-G  Leu-2a  G  3.9  4.5  38 
F anti-H  0  H  58.5  6.4  35 
F anti-H  Leu-2a  H  4.6  0.0  0 
I anti-J  0  J  36.7  10.9  36 
! anti-J  Leu-2a  J  7.6  3.4  34 
The  impact  of Leu-2a  antibodies  on  target  binding  and  lysis was measured,  similar to 
that presented  in Table I. 
Discussion 
A  number  of immune  reactions  are  modified  by  the  presence  of monoclonal 
antibodies with affinity for participating cells. In the work presented here, we directed 
our attention  to  the  effects of some T-specific antibodies  on a  short-term  immune 
reaction, the effector phase of cell mediated lysis. In a panel of six anti-human T  cell 
antibodies and one directed at the monocyte series anti-OKT3, binding to all T  cells 
and anti-Leu-2a and anti-OKT8, detecting the cytotoxic/suppressive T  cell  subset, 
were  shown  to  prevent  CTL  but  not  NK  activity.  This  selectivity  makes  these 
antibodies useful for assigning a  particular lytic activity to one or the other effector 
classes.  Leu-2a and OKT3 antibodies were investigated in greater detail.  Both were 
shown to prevent CTL activity by an interaction with the effector cell, using non-T 
target cells.  A difference for the two antibodies was noted in that Leu-2a antibodies 
required  being present  in  the  assay to exert  their  full  inhibition,  whereas  washing 
away free OKT3 antibody before the assay did not influence inhibition. This allows 
for treatment  with this latter antibody of large numbers of cells in a  small volume 
before  adding  them  to  the  test.  OKT3  antibody  concentrations  from  20  ng/ml 
reproducibly induced detectable inhibition. 
The lytic process by CTL cells  has  been  separated  in  several  distinct  steps  (16). 
Inhibition of lysis could result  from interference with several of these steps. A single 
cell  assay contributes important information. With this technique, the reduced lysis 
observed after  anti-OKT3  treatment  was shown  not  to  result  from  reduced  target LANDEGREN ET AL.  BRIEF  DEFINITIVE REPORT  1583 
binding, but rather the ability to lyse bound cells was impeded. The Leu-2a antibody, 
in contrast, caused a diminished binding of target cells by antibody-treated effectors. 
The ability of the Leu-2a antibody to affect the target binding step of CTL activity 
as well as the rapid reversibility of the effects of antibody treatment accord with what 
has been shown for antibodies to the Lyt-2 antigen in the mouse (17, 18). A homology 
between these two antigens has been proposed because of similarities in structure and 
occurrence together with the effects upon lymphocyte stimulation and execution of 
lytic activity by antibodies to these antigens  (3). The mouse Lyt-2 antigen has been 
shown to be coded for by a  gene segment closely linked to that for the kappa chain 
(19).  The expression of the Lyt-2 antigen has been suggested to primarily correlate 
with  the  class  of major  histocompatibility complex antigen  perceived by the  cell 
rather than with  it's  function  (20).  Together with  the  impaired target  binding by 
CTL cells in the presence of Lyt-2 antibodies, these observations suggest a relatedness 
of this antigen to the antigen recognition structure on cytotoxic T  cells. The results 
presented here strengthen the analogy between the human  Leu-2a antigen and the 
Lyt-2  antigen  in  the  mouse  and  in  consequence  point  to  Leu-2a  as  an  antigen 
potentially forming part of a human antigen recognition structure on T  cells.  Such a 
role has previously been suggested for the OKT3 antigen  (7). The failure of OKT3 
antibodies to detectably affect target binding  in  doses that  severely depress target 
lysis makes this concept less  tenable. The intriguing effects of the OKT3 antibody, 
including low dose mitogenicity (7), and in higher concentrations, blocked prolifera- 
tive responses by T  cells  (6)  and  inhibited CTL activity via a  mechanism  distinct 
from  target  recognition  (this  paper),  however,  indicate  a  crucial  function  of this 
antigen.  Taken  together, these two antibodies,  here subjected to analysis, by their 
different ways of affecting cell function constitute attractive tools for the investigation 
of T  lymphocyte activity in general and specifically as it applies to the lytic phase of 
a response. 
Summary 
Out of a  panel of seven monoclonal antibodies with affinity for human lymphoid 
cells, three were shown  to prevent cytotoxic T  cell activity, whereas  none affected 
natural killer cell activity when applied without complement. Anti-OKT3 and anti- 
Leu-2a, with affinity for all T  cells and the cytotoxie/suppressive subset, respectively, 
were both shown to inhibit T  killing by their interaction with the effector cell. For 
anti-OKT3, the inhibition remained after free antibody was washed away. Anti-Leu- 
2a, in contrast, induced a rapidly reversible inhibition. Using a single cell assay, anti- 
OKT3 was  shown  to reduce the lytic ability without  affecting target cell binding, 
whereas anti-Leu-2a prevented the effectors from binding target cells. 
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